Danielle Robinson, James McFadyen, Eileen Merriman, Tan Chee Wee, Ross Baker, Huyen Tran
{"title":"Updated recommendations for warfarin reversal in the setting of four-factor prothrombin complex concentrate.","authors":"Danielle Robinson, James McFadyen, Eileen Merriman, Tan Chee Wee, Ross Baker, Huyen Tran","doi":"10.5694/mja2.52538","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Warfarin (vitamin K antagonist) remains an established anticoagulant for patients at high risk of arterial and venous thromboembolism. The prompt reversal of the anticoagulant effect of warfarin is necessary in the context of major bleeding or emergency surgery because of its extended inhibition of vitamin K-dependent coagulation factors for days. The mainstay of urgent warfarin reversal has been vitamin K administration, and infusion of a three-factor prothrombin complex concentrate (3FPCC) and the option for the addition of fresh frozen plasma as a source of factor VII. With the upcoming introduction in Australia and New Zealand of a four-factor prothrombin complex concentrate (4FPCC), which replaces all the vitamin K-dependent clotting factors, this article updates the previously published warfarin reversal guidelines.</p><p><strong>Main recommendations: </strong>For urgent warfarin reversal, 4FPCC should be used instead of 3FPCC, using the same suggested dose. Vitamin K co-administration is still recommended for more sustained reversal.</p><p><strong>Changes in management as a result of this statement: </strong>The use of 4FPCC for urgent warfarin reversal obviates the need for co-administration of fresh frozen plasma.</p>","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":" ","pages":""},"PeriodicalIF":6.7000,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Journal of Australia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5694/mja2.52538","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Warfarin (vitamin K antagonist) remains an established anticoagulant for patients at high risk of arterial and venous thromboembolism. The prompt reversal of the anticoagulant effect of warfarin is necessary in the context of major bleeding or emergency surgery because of its extended inhibition of vitamin K-dependent coagulation factors for days. The mainstay of urgent warfarin reversal has been vitamin K administration, and infusion of a three-factor prothrombin complex concentrate (3FPCC) and the option for the addition of fresh frozen plasma as a source of factor VII. With the upcoming introduction in Australia and New Zealand of a four-factor prothrombin complex concentrate (4FPCC), which replaces all the vitamin K-dependent clotting factors, this article updates the previously published warfarin reversal guidelines.
Main recommendations: For urgent warfarin reversal, 4FPCC should be used instead of 3FPCC, using the same suggested dose. Vitamin K co-administration is still recommended for more sustained reversal.
Changes in management as a result of this statement: The use of 4FPCC for urgent warfarin reversal obviates the need for co-administration of fresh frozen plasma.
简介华法林(维生素 K 拮抗剂)仍然是动脉和静脉血栓栓塞高危患者的首选抗凝剂。由于华法林对维生素 K 依赖性凝血因子的抑制作用可持续数天,因此在大出血或急诊手术中必须及时逆转华法林的抗凝作用。紧急逆转华法林的主要方法是服用维生素 K、输注三因子凝血酶原复合物浓缩物(3FCC)以及添加新鲜冰冻血浆作为 VII 因子来源。澳大利亚和新西兰即将引入四因子凝血酶原复合物浓缩物(4FCC),该浓缩物可替代所有依赖维生素 K 的凝血因子,因此本文对之前发布的华法林逆转指南进行了更新:主要建议:对于紧急华法林逆转,应使用 4FPCC 代替 3FCC,建议剂量相同。仍建议联合应用维生素 K 以获得更持久的逆转效果:使用 4FPCC 进行紧急华法林逆转时,无需联合应用新鲜冰冻血浆。
期刊介绍:
The Medical Journal of Australia (MJA) stands as Australia's foremost general medical journal, leading the dissemination of high-quality research and commentary to shape health policy and influence medical practices within the country. Under the leadership of Professor Virginia Barbour, the expert editorial team at MJA is dedicated to providing authors with a constructive and collaborative peer-review and publication process. Established in 1914, the MJA has evolved into a modern journal that upholds its founding values, maintaining a commitment to supporting the medical profession by delivering high-quality and pertinent information essential to medical practice.